Long-term follow-up of first-line chemotherapy with or without camrelizumab for advanced non-squamous NSCLC

The multicenter phase 3 CameL trial in China evaluated addition of camrelizumab to first-line carboplatin and pemetrexed chemotherapy for advanced non-squamous NSCLC. Long-term follow-up of the trial (minimum 43.9 months after randomization of the last patient) found median overall survival 27.1 months in the camrelizumab-chemotherapy group versus 19.8 months in the chemotherapy group (HR 0.72; 95% CI 0.57-0.92). After adjustment for crossover, the survival benefit with addition of camrelizumab was more pronounced (HR 0.55; 95% CI 0.42-0.71). The toxicity was manageable. The authors conclude that these results support the use of camrelizumab combination as first-line therapy for advanced non-squamous NSCLC.